chfr PROGRAM AND ABSTRACTS OSLO, NOR Y

Size: px
Start display at page:

Download "chfr PROGRAM AND ABSTRACTS OSLO, NOR Y"

Transcription

1 10 th AnnuAl chfr symposium PROGRAM AND ABSTRACTS Holmenkollen Park Hotel Rica september 20 21, 2012 OSLO, NORY

2 content 3 Preface 4 General information 5 Information for speakers and poster presenters 6 Program 8 Poster sessions 14 Abstracts Poster session I 25 Abstracts Poster session II 35 Abstracts Poster session III 46 Abstracts Poster session IV 58 Abstracts Poster session V 69 Abstracts Poster session VI 78 Participants 82 Notes Center for Heart Failure Research Program 2 10 th AnnuAl chfr symposium

3 dear Participant We are very pleased to welcome you to the 10th Annual CHFR Symposium. We look forward to a very exciting meeting, fruitful discussions and scientific interactions. The Center for Heart Failure Research constitutes a branch of medical research within the Faculty of Medicine at the University of Oslo, Norway. It is financially supported by the University and the South-Eastern Norway Regional Health Authority (Helse Sør-Øst). The Center represents the concerted action of groups with complementary expertise combining state-of-the-art gene technology and capabilities to investigate protein function in experimental systems. The systems range from isolated cells and multicellular preparations to integrative physiology in pathophysiological models of heart failure. The clinical research groups of the Center for Heart Failure Research allow for testing of hypotheses in prospective clinical studies. The Center also organizes the PhD School of Heart Research that provides a high quality program specifically aimed at qualifying PhD students for future careers in heart research. The School hosts an annual introductory course as well as workshops for ongoing projects, and it provides a network for collaborations and exchange of methods and ideas within the Center. The Center also organizes the required mid-term evaluation (midtveisevaluering) of the PhD candidates in the field of heart research. Financial support to organize this meeting was obtained from the Research Council of Norway. Our main aim is to promote and integrate high quality research from bench to bedside in the field of heart failure. Steering committee, Center of Heart Failure Research Stefan Agewall, Geir Øystein Andersen, Harald Arnesen, Dan Atar, Håvard Attramadal, Reidar Bjørnerheim, Thor Edvardsen, Lars Gullestad, John Kjekshus, Finn Olav Levy, Torbjørn Omland, Jan-Bjørn Osnes, Helge Røsjø, Ole M. Sejersted, Ingebjørg Seljeflot, Ivar Sjaastad, Tor Skomedal, Otto Smiseth, Petter Andreas Steen, Theis Tønnessen, Guro Valen and Geir Christensen Organizing commitee: Fredrik Swift, Mathis Stokke, Geir Christensen 10 th AnnuAl chfr symposium 3

4 General information Venue All events take place at Holmenkollen Park Hotel Rica, Oslo ( The hotel is nicely located 350 m above sea level, overlooking Oslo. The scientific sessions are held in Saga Hall. Registration On the first day of the meeting please collect your badge and program at the registration desk as soon as possible upon arrival. The registration desk is located near Saga Hall. How to get there? By car: E18 South-west (from Drammen/Sandvika): Follow the signs to Ring 3 and Smestad. At Smestad, follow the signs to Holmenkollen. E6/E18 South-east (from Gothenburg/Stockholm): Follow the signs to Drammen, through Oslo city centre. Then follow the signs to Ring 3 and Smestad. At Smestad, follow the signs to Holmenkollen. E6 North (Oslo Airport, Gardermoen): After passing the toll booths, keep to the right and head towards Ring 3 Sinsen and Smestad. At Smestad, follow the signs to Holmenkollen. Parking: The hotel offers free parking in designated parking spots before the final approach to the hotel, in addition to indoor parking for a fee in the hotel s parking garage. With public transport: From the airport: Upon arrival at Oslo Airport, Gardermoen, you can take the Airport Train directly to Oslo Central Station (Oslo S); trains depart every 10 minutes. Travel time is approximately 20 minutes, and the cost is NOK From the Central Station (Oslo S): Take underground #1 "Frognerseteren" and get off at the Holmenkollen Station. The ride takes approximately 20 minutes. Follow the road uphill towards the Holmenkollen National Ski Stadium. It is a 10 minute walk, and slightly uphill. Taxi from the Central Station (Oslo S): The taxi journey takes approx 20 minutes, and the cost is NOK , depending on what time you will be travelling and number of passengers. Airport Taxi: To get special prices by taxi from the Gardermoen Airport directly to the Holmenkollen Park Hotel Rica, just contact the Airport Taxi stand, next to the arrival gate inside or pre-order at: Coffee Coffee, tea and soft drinks will be available in the lobby during breaks. Lunch Lunch is offered on both days of the meeting in Galleriet close to the main entrance th AnnuAl chfr symposium

5 Information for speakers and posters presenters Oral presentations Please leave no less than 5 min at the end of your talk for discussion. We ask you to prepare your presentation in PowerPoint. A Windows computer with PowerPoint 2007 installed will be on-site. You must bring your presentation on a USB memory stick or CD at least one hour before your presentation starts. Alternatively, you can your presentation to fredrik.swift@medisin.uio.no before September 14, at 18:00 (Central European Time). If you have any questions regarding the electronic presentations, or if you wish to verify the compatibility of your presentation, please contact: Fredrik Swift fredrik.swift@medisin.uio.no Phone: Poster presentations Posters will be mounted with push-pins, which will be available on-site. Please mount your posters on Thursday morning and according to the number assigned in the program. Please leave your posters mounted until the end of the day. Posters left behind will be discarded. A prize of NOK 5000,- will be awarded to the author of the best poster in each session. The criteria are: 1) Novelty of conclusions. 2) Quality of data. 3) Clarity of presentation (purpose, results, conclusions). Poster categories: I. Biomarkers and cardiac disease II. Cellular signaling: myocardial hypertrophy and ischemia III. Cardiac function during heart failure and exercise training IV. Cellular signaling: myocardial function and arrhythmias V. Diagnostic and therapeutic strategies for cardiac disease VI. Inflammatory mediators and heart disease Recommended poster size: 90x120 cm The poster should be presented orally in maximally 3 minutes followed by 4-5 minutes discussion. Please do not exceed this time in your presentation since there is only a limited time available for the moderated poster sessions. 10 th AnnuAl chfr symposium 5

6 PROGRAM Thursday September 20, :00 08:30 Registration 08:30 08:45 Erlend B. Smeland, Director for Research, Innovation and Education Oslo University Hospital Opening remarks Session A: Opening session Chairs: Torbjørn Omland, AUH, UoO and Harald Arnesen, OUH, UoO 08:45 09:25 Marc A. Pfeffer, Brigham and Women's Hospital, Boston, USA Surprises from clinical outcome trials 09:25 09:40 Break Session B: Moderated poster sessions (09:40 11:30) I. Biomarkers and cardiac disease Moderators: Helge Røsjø, Akershus University Hospital and Erik Øie, Diakonhjemmet Hospital and Oslo University Hospital II. Cellular signaling: myocardial hypertrophy and ischemia Moderators: Kirsti Ytrehus and Terje Larsen, University of Tromsø III. Cardiac function during heart failure and exercise training Moderators: Ulrik Wisløff and Øyvind Ellingsen, Norwegian University of Science and Technology, Trondheim IV. Cellular signaling: myocardial function and arrhythmias Moderators: Mathis K. Stokke and William E. Louch, Oslo University Hospital V. Diagnostic and therapeutic strategies for cardiac disease Moderators: Arnljot Tveit, Vestre Viken Hospital Trust and Eva Gerdts, University of Bergen 11:30 12:30 Lunch VI. Inflammatory mediators and heart disease Moderators: Arne Yndestad and Ingebjørg Seljeflot, Oslo University Hospital Session C: Myocardial signaling and new therapeutic approaches Chairs: Jan-Bjørn Osnes and Finn Olav Levy, UoO 12:30 13:10 Sian E. Harding, Imperial College, London, UK Takotsubo cardiomyopathy a disease or a rescue from sudden cardiac death? 13:10 13:50 Paul C. Simpson, University of California, San Francisco, USA Alpha-1-adrenergic receptor agonists to treat heart failure 13:50 14:20 Break Session D Resynchronization and stem cell therapy Chairs: Theis Tønnessen and Dan Atar, OUH and UoO 14:20 15:00 Scott Solomon, Brigham and Women's Hospital, Boston, USA Strain, synchrony and speckle: myocardial function in the CRT patient 15:00 15:40 James T. Willerson, Texas Heart Institute, Houston, USA Stem cells in the treatment of patients with heart failure and coronary heart disease 6 10 th AnnuAl chfr symposium

7 Friday September 21, 2012 Session E: Diastolic heart failure Chairs: Ole M. Sejersted and Otto A. Smiseth, OUH, UoO 08:15 08:55 Walter J. Paulus, Free University Medical Center Amsterdam, the Netherlands Competing risk factors for diastolic heart failure 08:55 09:35 Barry A. Borlaug, Mayo Clinic Rochester, Minnesota, USA Cardiovascular reserve function during exercise in heart failure with preserved ejection fraction 09:35 10:05 Break Session F: Mechanisms of heart failure and cardiac resynchronization Chairs: Håvard Attramadal, OUH, UoO and William E. Louch, OUH 10:05 10:45 Evangelia Kranias, University of Cincinnati, USA Sarcoplasmic reticulum calcium cycling circuits in heart failure 10:45 11:25 David Kass, Johns Hopkins School of Medicine, Baltimore, USA The reverse engineering of cardiac resynchronization 11:30 12:30 Lunch Session G: Diagnostics of cardiomyopathies and arrhythmias Chairs: Thor Edvardsen and Ivar Sjaastad, OUH, UoO 12:30 13:10 Michael J. Ackerman, Mayo Clinic Rochester, Minnesota, USA State of genetic testing for the structural cardiomyopathies 13:10 13:50 Kristina Haugaa, Oslo University Hospital, Norway How to predict ventricular arrhythmias by echocardiography 13:50 14:20 Break Session H: Inflammation in heart failure and new therapeutic strategies Chairs: Lars Gullestad, OUH, UoO and Guro Valen, UoO 14:20 15:00 Nikolaos G. Frangogiannis, Albert Einstein College of Medicine, New York, USA Inflammation in cardiac remodeling and heart failure 15:00 15:40 Fady I. Malik, Cytokinetics, Inc., San Francisco, USA Discovery and development of the cardiac myosin activator, omecamtiv mecarbil, for systolic heart failure 15:40 16:00 Presentation of prize winners AUH: Akershus University Hospital OUH: Oslo University Hospital UoO: University of Oslo 10 th AnnuAl chfr symposium 7

8 Poster session I Biomarkers and cardiac disease Moderators: Helge Røsjø, Akershus University Hospital, Erik Øie, Diakonhjemmet Hospital and Oslo University Hospital P01 P02 P03 P04 P05 P06 P07 P08 p09 p10 Low-level concentrations of cardiac troponin I is associated with severity of obstructive sleep apnea Einvik G, Randby A, Røsjø H, Omland T Increased Prevalence of Elevated High-Sensitivity Cardiac Troponin T among Patients with Stable Chronic Obstructive Pulmonary Disease Neukamm A, Høiseth AD, Søyseth V, Omland T Stable vs. dynamic elevation of cardiac troponin T during COPD exacerbation Høiseth AD, Omland, T, Hagve, TA, Brekke PH, Søyseth V Physician accuracy for diagnosing heart failure in unselected patients hospitalised with dyspnoea data from the Akershus Cardiac Examination (ACE) 2 study Brynildsen J, Høiseth AD, Christensen G, Omland T, Røsjø H Prothrombotic Markers in Patients with Acute Myocardial Infarction and Left Ventricular Thrombus Formation Treated with PCI and Dual Antiplatelet Therapy Solheim S, Seljeflot I, Lunde K, Bratseth V, Aakhus S, Forfang K, Arnesen H Markers of Endothelial and Platelet Activation are Associated with High On-Aspirin Residual Platelet Reactivity Pettersen AÅ, Arnesen H, Opstad TB, Bratseth V, Seljeflot I Low levels of IgM antibodies against phosphorylcholine are not associated with glucometabolic disturbances in patients with acute ST-elevation myocardial infarction Knudsen EC, Seljeflot I, Müller C, Andersen GØ IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to final infarct size and clinical outcome Knudsen EC, Seljeflot I, Müller C, Andersen GØ Bradykinin enhances nerve-induced cardiac tpa release possibly by transactivation of the ß2-adrenergic receptor Aspelin T, Eriksen M, Ilebekk A and Lyberg T Secreted frizzled related protein 3 predicts outcomes in chronic heart failure: A Controlled Rosuvastatin Multinational Trial In Heart Failure (CORONA) substudy Askevold ET, Gullestad L, Nymo S, Michelsen AE, Yndestad A, Kjekshus J, McMurray JJV, Aukrust P and Ueland T 8 10 th AnnuAl chfr symposium

9 Poster session II Iı Cellular signaling; myocardial hypertrophy and ischemia Moderators: Kirsti Ytrehus, UoT and Terje Larsen, UoT P11 P12 P13 P14 The mechanisms of the DNA glycosylase Neil3 in remodelling and regeneration following myocardial infarction Olsen MB, Finsen AV, Hildrestrand GA, Sjaastad I, Vinge LE, Louch W, Sandanger Ø, Neurater CG, Luna L, Gullestad L, Christensen G, Aukrust P, Yndestad A and Bjørås M Syndecan-4 Regulates Cardiac Myofibroblast Differentiation and Extracellular Matrix Production by Signaling via NFAT in Response to Mechanical Stress Herum KM, Lunde IG, Skrbic B, Florholmen G, Behmen D, Sjaastad I, Carlson CR, Gomez MF, Geir Christensen The adhesion site transmembrane proteoglycan syndecan-4; an integrator of pro-hypertrophic and pro-inflammatory signaling in the heart? Strand ME, Herum KLM, Rana ZA, Skrbic B, Vistnes M, Hasic A, Kvaløy H, Sjaastad I, Tønnessen T, Carlson CR, Christensen G, Lunde IG Aortic stenosis in mice and men; myocardial activation of the four calcineurin-dependent NFAT transcription factor isoforms is attenuated by relief of pressure overload Lunde IG, Skrbic B,Tønnessen T, Kvaløy H, Enger U, Sjaastad I, Christensen G, Carlson CR P15 P16 P17 P18 P19 Reduction in collagen type 8 might be involved in transition from compensated hypertrophy to left ventricular dilatation and overt heart failure in pressure overload Skrbic B, Engebretsen KVT, Marstein HS, Sjaastad I, Christensen G, Bjørnstad JL, Tønnessen T LXRs improve cardiac function in the murine ischemia reperfusion model Lei P, Valen G, Haugen F Antifibrotic effect of p66shca protein deletion in myocardial infarction Baysa A, Di Lisa F, Giorgio M, Vaage J, Valen G Matricellular CCN2-mediated Postconditioning of The Heart Reduces Infarct Size in Ischemia/ Reperfusion Injury by Direct Activation of The Akt/GSK-3β Signaling Cascade in Cardiac Myocytes Ole Jørgen Kaasbøll, Ingvild Tronstad Moe, Else Marie Valbjørn Hagelin, M. Shakil Ahmed, and Håvard Attramadal The Matricellular Protein CCN2/CTGF Alters Remodeling and Fibrotic Response Following Myocardial Infarction in Mice Florholmen G, Kaasbøll OJ, Gravning J, Hagelin EM, Ahmed MS, Attramadal H 10 th AnnuAl chfr symposium 9

10 Poster session III Cardiac function during heart failure and exercise training Moderators: Ulrik Wisløff, Norwegian University of Science and Technology, Trondheim Øyvind Ellingsen, Norwegian University of Science and Technology, Trondheim P20 TMEM8A 1080A>G Polymorphism in a 3 UTR MicroRNA Target Site Influences Aerobic Capacity in Health Individuals: the HUNT Study Silva GJJ, Afonso de Almeida MA, Bye MA, Blangero J, Wisløff U P21 Short-term protocols are sufficient to induce exercise effects in rodents Danielsen TK, Manotheepan R, Sadredini M, Aronsen JM, Sejersted OM, Sjaastad I, Stokke MK P22 Exercise training prevent obesity-induced impairment of myocardial function and mechanoenergetics, as well as mitochondrial capacity and fatty acid-induced proton leak Hafstad AD, Lund J, Larsen TS, Aasum E P23 Effects of physical training on intercellular cardiomyocytes and cardiac fibroblasts coupling after myocardial infarction Alves, MA; Kaur, P; Moreira, JB; Stolen, T; Rolim, N; Rosbjorgen, R; Silva, G; Wisloff, U P24 Beneficial effects on Aerobic Capacity and Threshold Heart Rate for Arrhythmias from Exercise Training in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia R Manotheephan, J Saberniak, TK Danielsen, T Edvardsen, I Sjaastad, KH Haugaa, MK Stokke P25 Early deterioration of right ventricular function in patients with chronic obstructive pulmonary disease; a combined right heart catheterization and echocardiographic study HQ Pham, SK Namtvedt, H Røsjø, T Omland, K Steine, TG v. Lueder P26 Reduced left ventricular systolic strain in patients with obstructive sleep apnoea evidenced by speckle-tracking echocardiography HQ Pham, SK Namtvedt, H Røsjø, T Omland, K Steine, TG v. Lueder P27 Elevated preload is critical for synchronization of myocardial lengthening (é) and mitral inflow (E) in ischemic acute heart failure complicated with tachycardia How OJ, Næsheim T, Bakkehaug JP, Kondratiev T, Remme EW and Myrmel T P28 Wasted work fraction A novel method for assessing the negative mechanical impact of dyssynchrony in patients with left bundle branch block Russell K, Eriksen M, Aaberge L, Wilhelmsen N, Remme EW, Skulstad H, Gjesdal O, Opdahl A, Kongsgård E, Edvardsen T, Smiseth OA P29 Detailed assessment of the contractility in the infarcted heart using high-resolution MRI phase contrast velocimetryt Espe EKS, Aronsen JM, Hougen K, Skogestad J, Louch WE, Sejersted OM, Zhang L, Sjaastad I th AnnuAl chfr symposium

11 Poster session IV Cellular signaling: myocardial function and arrhythmias Moderators:Mathis K. Stokke, Oslo University Hospital, William E. Louch, Oslo University Hospital P30 P31 P32 P33 P34 P35 P36 P37 p38 p39 p40 Variable t-tubule density and excitation-contraction coupling in rat atrial cardiomyocytes Frisk M, Sejersted OM and Louch WE Ca 2+ wave probability in rats with varying levels of cardiac contractile dysfunction after myocardial infarction Sadredini M, Danielsen TK, Aronsen JM, Sjaastad I, Stokke MK Ca 2+ wave velocity in cardiomyocytes is regulated by ryanodine receptor Ca2+ sensitivity and SR Ca2+ content Kristian O. Loose, Mani N. Sadredini, Ole M. Sejersted, Mathis K. Stokke, William E. Louch Secretoneurin is an Inhibitor of CaMKII Activity in Heart Ottesen AH, Louch WE, Carlson C, Landsverk OJB, Stridsberg M, Omland T, Christensen G, Røsjø H Extracellular potassium regulates Ca2+ homeostasis through interaction between NCX and NKA Skogestad J, Aronsen JM, Hougen K, Stokke MF, Swift F, Sejersted OM, Sjaastad I Oxidative inhibition of erythrocyte Na-K pump in heart failure: a novel, pathophysiologically relevant biomarker GA Figtree, CC Liu, N Fry, HH Rasmussen Calpain induces cleavage of the cardiac Na+- Ca2+ exchanger 1 (NCX1) in failing hearts: Molecular interaction P Wanichawan, I.G Lunde, JM Aronsen, B Austbø, M. Lunde, T Tønnessen, I Sjaastad, O M Sejersted and CR Carlson Compartmented production and degradation of camp by β-adrenergic, prostanoid and 5-HT4 receptors in CHF, visualized by FRET-based camp sensors Dugstad KS, Andressen KW, Aronsen JM, Sjaastad I, Zaccolo M and Levy FO Blockade of inhibitory G protein constitutive activation reveals adenylyl cyclase type 6 dependent regulation of contractile force in mouse ventricle Melsom CB, Lai NC, Hammond HK, Dessauer CW, Aronsen JM, Sjaastad I,Levy FO & Krobert KA PDE3A is part of the SERCA2-AKAP18δ macromolecular complex in in cardiomyocytes Hougen K, Aronsen JM, Skogestad J, Enger U, Moltzau LR, Qvigstad E, Skomedal T, Taskén K, Carlson CR, Sjaastad I Development of specific inhibitors of the PKA-AKAP18δ-Phospholamban complex Østensen E, Lygren B, Taskén K and Klaveness J 10 th AnnuAl chfr symposium 11

12 Poster session V Diagnostic and therapeutic strategies for cardiac disease Moderators: Arnljot Tveit, Vestre Viken Hospital Trust, Eva Gerdts, University of Bergen P41 P42 P43 P44 P45 P46 P47 P48 p49 p50 Low Heart Rate at Rest and during Exercise Predict Incident Atrial Fibrillation in Healthy Middle-aged Men Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Gjesdal K, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J Comparison of Four Single-Drug Regimens on Ventricular Rate and Arrhythmia-Related Symptoms in Patients with Permanent Atrial Fibrillation Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A Calcium Channel Blockers Improve Exercise Capacity and Lower NT-proBNP Levels Compared to Beta Blockers in Patients with Permanent Atrial Fibrillation Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A Effect on plasma d-dimer levels of angiotensin receptor blockade and maintained sinus rhythm after electrical cardioversion for persistent atrial fibrillation Tveit A, De Caterina R, Smith P, Arnesen H, Seljeflot I Primary Percutaneous Coronary Intervention for acute ST-segment Elevation Myocardial Infarction in Octogenarians PA. Claussen, J. Eritsland, GØ. Andersen, C Holst-Hansen, M. Ziener, A. Mangschau, D. Atar, S. Halvorsen Levosimendan improves regional contractility in post-ischemic myocardium in patients with acute PCI- treated STEMI complicated by symptomatic heart failure Husebye T, Eritsland J, Arnesen H, Seljeflot I, Sandvik L, Mangschau A, BjørnerheimR, Andersen GØ Effect of Obesity on Cardiovascular Events in Asymptomatic Aortic Stenosis (a SEAS Substudy) Rogge B, Cramariuc D, Lønnebakken MT, Rieck AE, Gohlke-Baerwolf C, Chambers JB, Boman K, Gerdts E PRevention of cardiac Dysfunction during Adjuvant breast cancer therapy PRADA Gulati G, Heck SL, Ree AH, Bratland Å, Steine K, Shulz-Menger J, Gravdehaug B, Hoffmann P, Røsjø H, Geisler J, Omland T Atrioventricular Conduction Delay and predicts Ventricular Tachycardia in Lamin A/C Mutation Carriers Hasselberg NE, Edvardsen T, Petri H, Berge KE, Leren TP, Bundgaard H, Haugaa KH High level of physical activity may impair myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy Jørg Saberniak, Nina Eide Hasselberg, Anders G Holst, Thor Edvardsen, Kristina H. Haugaa th AnnuAl chfr symposium

13 Poster session VI Inflammatory mediators and heart disease Moderators: Arne Yndestad, Oslo University Hospital, Ingebjørg Seljeflot, Oslo University Hospital P51 P52 P53 P54 P55 P56 P57 P58 P51: The IL A/G polymorphism is associated with clinical events in CAD Opstad, TB, Pettersen, AÅ, Åkra, S Arnesen, H, Seljeflot, I Effect of clopidogrel and aspirin on circulating fractalkine (CX3CL1) level in patients with stable coronary artery disease (CAD) Njerve IU, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I Inflammatory cytokines in chronic heart failure Staale H Nymo, Thor Ueland, Johannes Hulthe, Pål Aukrust, Arne Yndestad, Lars Gullestad Altered fatty acid profile and gene expression in epicardial adipose tissue of heart failure patients Fosshaug LE, Dahl CP, Risnes I, Olstad OK, Berge RK, Nymo S, Gullestad L, Aukrust P, Yndestad A, Vinge LE, and Øie E Nucleosomes in heart failure Staale H. Nymo, Thor Ueland, Christen P. Dahl, Erik T. Askevold, Leif Erik Vinge, Lars Gullestad, Pål Aukrust, Arne Yndestad Mitochondrial DNA is a putative activator of cardiac fibroblast Toll-like receptor 9 during myocardial infarction Ohm, I.K., Sandanger, Ø., Finsen, A.V., Bliksøen, M., Valen, G., Solheim, S., Kaasbøll, O.J., Attramadal, H., Yndestad, A., Vinge, L.E. NLRP3 deficiency increases myocardial ischemia-reperfusion injury Sandanger Ø, Gao E, Nymo S, Ranheim T, Bliksøen M, Alfsnes K, Lien E, Aukrust P, Vinge LE, Yndestad A The collagen-organizing proteoglycan lumican is increased in experimental and clinical heart failure and its production by cardiac fibroblasts is induced by pro-inflammatory and mechanical stimuli Engebretsen KVT, Lunde IG, Waehre A, Strand ME, Sjaastad I, Marstein H, Skrbic B, Dahl CP, Christensen G, Bjørnstad JL, Tønnessen T 10 th AnnuAl chfr symposium 13

9 th AnnuAl chfr symposium

9 th AnnuAl chfr symposium 9 th AnnuAl chfr symposium PROGRAM AND ABSTRACTS September 15 16, 2011 Holmenkollen Park Hotel Rica, Oslo, Norway Center for Heart Failure Research content dear Participant We are very pleased to welcome

More information

8th Annual Chfr Symposium

8th Annual Chfr Symposium COVER 8th Annual Chfr Symposium Program and ABSTRACTS September 30 October 01, 2010 Center for Heart Failure Research 20ı0 Dear Participant, We are very pleased to welcome you to the 8th Annual CHFR Symposium.

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Lecture Outline. Cardiovascular Physiology. Cardiovascular System Function. Functional Anatomy of the Heart

Lecture Outline. Cardiovascular Physiology. Cardiovascular System Function. Functional Anatomy of the Heart Lecture Outline Cardiovascular Physiology Cardiac Output Controls & Blood Pressure Cardiovascular System Function Functional components of the cardiovascular system: Heart Blood Vessels Blood General functions

More information

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation

More information

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence

More information

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical

More information

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long

More information

Diagnostic and Therapeutic Procedures

Diagnostic and Therapeutic Procedures Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,

More information

Evolving Challenges in Promoting Cardiovascular Health. November 4-5, 2011, BARCELONA. Final Agenda Feb 2011

Evolving Challenges in Promoting Cardiovascular Health. November 4-5, 2011, BARCELONA. Final Agenda Feb 2011 Evolving Challenges in Promoting Cardiovascular Health November 4-5, 2011, BARCELONA Final Agenda Feb 2011 SATELLITE PUBLIC LECTURE (LAY PUBLIC): Thursday, November 3, 2011 7:00 8:30 PM Health and Life

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.

More information

Hypertension and cardiovascular (CV) ageing Bridging basic research and clinical science

Hypertension and cardiovascular (CV) ageing Bridging basic research and clinical science Title: Hypertension and cardiovascular (CV) ageing Bridging basic research and clinical science Prior to seminar: Participants are selected by the organizing committee based on curriculum vitae and application

More information

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. Heart Failure EXERCISES Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. ) 1. Heart rate increase is a kind of economic compensation, which should

More information

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA 1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate

More information

Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen

Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen PhD course: Cardiac arrhythmias - Aim and content: Cardiac arrhythmia represents a wide spectrum of abnormalities

More information

INHERIT. The Lancet Diabetes & Endocrinology In press

INHERIT. The Lancet Diabetes & Endocrinology In press INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn

More information

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized

More information

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary

More information

SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, 2012. Cardiovascular Center OLV Clinic Aalst Belgium. and

SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, 2012. Cardiovascular Center OLV Clinic Aalst Belgium. and SECOND CARDIOLOGY JOINT SEMINAR Rome, April 12-13, 2012 Cardiovascular Center OLV Clinic Aalst Belgium and Cardiology Faculty of Medicine and Psychology Sapienza University, Rome, Italy Cardiology Sacred

More information

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications

More information

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias Cardiovascular System & Its Diseases Lecture #4 Heart Failure & Cardiac Arrhythmias Dr. Derek Bowie, Department of Pharmacology & Therapeutics, Room 1317, McIntyre Bldg, McGill University derek.bowie@mcgill.ca

More information

1 Congestive Heart Failure & its Pharmacological Management

1 Congestive Heart Failure & its Pharmacological Management Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Prof. Keith Baker 1 Congestive Heart Failure & its Pharmacological Management Keith Baker, M.D., Ph.D.

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

50 years of CRM Device Therapy Past, Present and Future. Richard Sutton Professor of Cardiology Imperial College, London, UK

50 years of CRM Device Therapy Past, Present and Future. Richard Sutton Professor of Cardiology Imperial College, London, UK 50 years of CRM Device Therapy Past, Present and Future Richard Sutton Professor of Cardiology Imperial College, London, UK The Past First implant 1958 Sweden Dual Chamber pacing (VAT) 1962 US Transvenous

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary

More information

Exchange solutes and water with cells of the body

Exchange solutes and water with cells of the body Chapter 8 Heart and Blood Vessels Three Types of Blood Vessels Transport Blood Arteries Carry blood away from the heart Transport blood under high pressure Capillaries Exchange solutes and water with cells

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT

More information

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea

More information

PhD-course. Danish Cardiovascular Research Academy and the Nordic Medical Research Councils

PhD-course. Danish Cardiovascular Research Academy and the Nordic Medical Research Councils PhD-course Danish Cardiovascular Research Academy and the Nordic Medical Research Councils Title of the course: Hypertension and cardiovascular ageing Bridging basic research and clinical science Aim:

More information

Rome, Italy December 4-7, 2012 Rome Cavalieri TIMETABLE

Rome, Italy December 4-7, 2012 Rome Cavalieri TIMETABLE Rome, Italy December 4-7, 2012 Rome Cavalieri Monday, December 3 ROOM Terrazza Monte Mario PATIENT MANAGEMENT CONCEPTS AND CONTROVERSIES IN ELECTROPHYSIOLOGY BIOTRONIK International Fellows Program (IFP)

More information

Automatic External Defibrillators

Automatic External Defibrillators Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Jeffrey M. Carlton Heart & Vascular Institute Presents

Jeffrey M. Carlton Heart & Vascular Institute Presents Jeffrey M. Carlton Heart & Vascular Institute Presents 6 th ANNUAL CARDIOLOGY UPDATE: NEW DEVELOPMENTS Program Director: Robert and Georgia Roth Endowed Chair for Excellence in Cardiac Care Saturday, September

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Introduction to Electrocardiography. The Genesis and Conduction of Cardiac Rhythm

Introduction to Electrocardiography. The Genesis and Conduction of Cardiac Rhythm Introduction to Electrocardiography Munther K. Homoud, M.D. Tufts-New England Medical Center Spring 2008 The Genesis and Conduction of Cardiac Rhythm Automaticity is the cardiac cell s ability to spontaneously

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

Heart Disease: Diagnosis & Treatment

Heart Disease: Diagnosis & Treatment How I Treat Cardiology Peer Reviewed Heart Disease: Diagnosis & Treatment Amara Estrada, DVM, DACVIM (Cardiology) University of Florida Background Clinical heart disease is the stage of disease when a

More information

INTRODUCTION TO EECP THERAPY

INTRODUCTION TO EECP THERAPY INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and

More information

The Copernican Revolution in Ischemic Heart Diseases: the day after

The Copernican Revolution in Ischemic Heart Diseases: the day after Menarini Foundation Symposia: 249 The Copernican Revolution in Ischemic Heart Diseases: the day after Pisa (Italy), June 27 th 28 th, 2014 Organized by POSTGRADUATE SCHOOL OF CARDIOVASCULAR MEDICINE UNIVERSITY

More information

Acquired, Drug-Induced Long QT Syndrome

Acquired, Drug-Induced Long QT Syndrome Acquired, Drug-Induced Long QT Syndrome A Guide for Patients and Health Care Providers Sudden Arrhythmia Death Syndromes (SADS) Foundation 508 E. South Temple, Suite 202 Salt Lake City, Utah 84102 800-STOP

More information

Recurrent AF: Choosing the Right Medication.

Recurrent AF: Choosing the Right Medication. In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

More information

Anaerobic and Aerobic Training Adaptations. Chapters 5 & 6

Anaerobic and Aerobic Training Adaptations. Chapters 5 & 6 Anaerobic and Aerobic Training Adaptations Chapters 5 & 6 Adaptations to Training Chronic exercise provides stimulus for the systems of the body to change Systems will adapt according to level, intensity,

More information

Brooklyn Stroke Symposium 2015

Brooklyn Stroke Symposium 2015 Brooklyn Stroke Symposium 2015 May 28, 2015 Brooklyn Public Library Grand Army Plaza Sponsored by Keynote Presentations Sleep Apnea and Stroke: More than a Snore Devin L. Brown, M.D., M.S. Professor of

More information

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH Giovanni Esposito, MD, PhD Dipartimento di Cardiologia, Cardiochirurgia ed Emergenze Cardiovascolari Laboratorio di Emodinamica

More information

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD. Ex parte VINOD SHARMA and DANIEL C. SIGG

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD. Ex parte VINOD SHARMA and DANIEL C. SIGG UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte VINOD SHARMA and DANIEL C. SIGG Appeal 2012-000284 Technology Center 1600 Before ERIC GRIMES, FRANCISCO C. PRATS,

More information

California Health and Safety Code, Section 1256.01

California Health and Safety Code, Section 1256.01 California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program

More information

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of

More information

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY 1. SCOPE AND METHODOLOGY 2. REPORT SYNOPSIS 2.1 General Definitions Myoblasts Pluripotent Cells Multipotent Cells Progenitor Cells Role of Stem Cells in Repairing the Heart Stem Cell Therapy Stem Cells

More information

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC

More information

Atrial Fibrillation Management Across the Spectrum of Illness

Atrial Fibrillation Management Across the Spectrum of Illness Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,

More information

Program Dag van Biofysica & Biomedische Technologie 13 November Nijmegen

Program Dag van Biofysica & Biomedische Technologie 13 November Nijmegen Program Dag van Biofysica & Biomedische Technologie 13 November Nijmegen Linnaeusgebouw, Heyendaalseweg 137, Campus Radboud University 9.30 Coffee and registration 10.00 Welcome Raymond van Ee, president

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

GENERAL HEART DISEASE KNOW THE FACTS

GENERAL HEART DISEASE KNOW THE FACTS GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to

More information

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is

More information

HEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise

HEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise WEEK 3 SUPPLEMENT HEART HEALTH A Beginner s Guide to Cardiovascular Disease HEART FAILURE Heart failure can be defined as the failing (insufficiency) of the heart as a mechanical pump due to either acute

More information

REFERENCE CODE GDHC443DFR PUBLICATION DATE JULY 2014 EVACETRAPIB (ACUTE CORONARY SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC443DFR PUBLICATION DATE JULY 2014 EVACETRAPIB (ACUTE CORONARY SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC443DFR PUBLICATION DATE JULY 2014 EVACETRAPIB (ACUTE CORONARY SYNDROME) - Executive Summary The table below provides a summary of the key metrics for Evacetrapib in the 7MM for Acute

More information

Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?

Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,

More information

Potential Causes of Sudden Cardiac Arrest in Children

Potential Causes of Sudden Cardiac Arrest in Children Potential Causes of Sudden Cardiac Arrest in Children Project S.A.V.E. When sudden death occurs in children, adolescents and younger adults, heart abnormalities are likely causes. These conditions are

More information

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate

More information

Resuscitation in congenital heart disease. Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto

Resuscitation in congenital heart disease. Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto Resuscitation in congenital heart disease Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto Evolution of Congenital Heart Disease Extraordinary success: Overall

More information

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,

More information

CHFR SYMPOSIUM Holmenkollen Park Hotel Rica October 11-12, 2007

CHFR SYMPOSIUM Holmenkollen Park Hotel Rica October 11-12, 2007 5th Annual CHFR SYMPOSIUM Holmenkollen Park Hotel Rica October 11-12, 2007 PROGRAM AND ABSTRACTS Center for Heart Failure Research 2007 Dear Friends and Colleagues, We warmly welcome you to our 5th Annual

More information

Summer School 2011 Berlin SFB Transregio 19

Summer School 2011 Berlin SFB Transregio 19 Summer School 2011 Berlin SFB Transregio 19 27th October 29th October 2011 Molecular Mechanisms and Consequences of Inflammatory Cardiomyopathy: State of the Art and Future Challenges Welcome Address

More information

Management of Pacing Wires After Cardiac Surgery

Management of Pacing Wires After Cardiac Surgery Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal

More information

Updated Cardiac Resynchronization Therapy Guidelines

Updated Cardiac Resynchronization Therapy Guidelines The Ohio State University Heart and Vascular Center Updated Cardiac Resynchronization Therapy Guidelines William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology

More information

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Srinivasan Rajagopal M.D. Assistant Professor Division of Cardiothoracic Anesthesia Objectives Describe the pathophysiology

More information

Protocol. Cardiac Rehabilitation in the Outpatient Setting

Protocol. Cardiac Rehabilitation in the Outpatient Setting Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 07/01/14 Next Review Date: 09/15 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,

More information

Advanced Heart Failure & Transplantation Fellowship Program

Advanced Heart Failure & Transplantation Fellowship Program Advanced Heart Failure & Transplantation Fellowship Program Curriculum I. Patient Care When on the inpatient Heart Failure and Transplant Cardiology service, the cardiology fellow will hold primary responsibility

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 Facts 4 million or so people have atrial fibrillation 16 billion dollars spent yearly in USA 30% of strokes attributable to AF and AFL 3-5

More information

Medical Tourism - The Role of Intervals inCardiovascular Cancer

Medical Tourism - The Role of Intervals inCardiovascular Cancer Acute Decompensated Heart Failure: Time Critical Interventions MO-51 / 1 Hour Faculty: Matthew Strehlow, MD, FACEP Monday, 10/26/2015 / 3:30 PM - 4:20 PM The treatment of congestive heart failure (CHF)

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

The P Wave: Indicator of Atrial Enlargement

The P Wave: Indicator of Atrial Enlargement Marquette University e-publications@marquette Physician Assistant Studies Faculty Research and Publications Health Sciences, College of 8-12-2010 The P Wave: Indicator of Atrial Enlargement Patrick Loftis

More information

Innovations and New Treatment Strategies in Heart Failure

Innovations and New Treatment Strategies in Heart Failure Innovations and New Treatment Strategies in Heart Failure 8th International Symposium, September 18th- 19th, 2015 Portorož, Slovenia Friday September 18th Morning Sessions 9.00-9.15 Opening Session 1 Heart

More information

SECTION I: Request. SECTION II: Need. Program Description

SECTION I: Request. SECTION II: Need. Program Description SECTION I: Request This is a formal request for the Utah CARMA Center to be formally recognized by the University of Utah as a large, collaborative medical and academic center whose focus is on comprehensive

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Pharmacology of the Respiratory Tract: COPD and Steroids

Pharmacology of the Respiratory Tract: COPD and Steroids Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart

More information

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Atrial Fibrillation and Heart Failure: A Cause or a Consequence Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November

More information

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015 Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.

More information

Contemporary Management of Cardiovascular Disease

Contemporary Management of Cardiovascular Disease Contemporary Management of Cardiovascular Disease NOVEMBER 20 21, 2015 Hilton Anatole Hotel Register Today! ccfcme.org/gocvdtx Contemporary Management of Cardiovascular Disease Join us on November 20-21

More information

Presenter Disclosure Information

Presenter Disclosure Information 2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.

More information

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine Graduate Certificate in Metabolic & Nutritional Medicine Graduate Certificate Metabolic & Nutritional Medicine Purpose

More information

5. Management of rheumatic heart disease

5. Management of rheumatic heart disease 5. Management of rheumatic heart disease The fundamental goal in the long-term management of RHD is to prevent ARF recurrences, and therefore, prevent the progression of RHD, and in many cases allow for

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Atrial Fibrillation The Basics

Atrial Fibrillation The Basics Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation

More information

R EFERENCES. Summary and conclusions

R EFERENCES. Summary and conclusions R EFERENCES Summary and conclusions 129 S UMMARY AND CONCLUSIONS SUMMARY AND GENERAL DISCUSSION 130 Constant vasodilatation, inhibition of platelet and monocyte adhesion, and local thrombolysis are the

More information

Innovation Platform: Sudden Cardiac Death

Innovation Platform: Sudden Cardiac Death Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Section Four: Pulmonary Artery Waveform Interpretation

Section Four: Pulmonary Artery Waveform Interpretation Section Four: Pulmonary Artery Waveform Interpretation All hemodynamic pressures and waveforms are generated by pressure changes in the heart caused by myocardial contraction (systole) and relaxation/filling

More information

Heart Failure: From Prevention to Intervention

Heart Failure: From Prevention to Intervention Sharp HealthCare Presents Heart Failure: From Prevention to Intervention Saturday, May 16, 2015 DoubleTree by Hilton Hotel San Diego - Mission Valley San Diego, Calif. As medical professionals, we know

More information